Lupin announces new chief executive of US market

MUMBAI: Lupin announced the appointment of Alok Sonig as CEO, US generics and global head generics R&D & biosimilars. Alok will lead and have overall responsibility for US generics business including research and development in India, and US, and commercial side of the business in US. He will also be responsible for Lupin’s global biosimilars business.

With over two decades of industry experience, Alok brings an established track record of success in the pharmaceutical and healthcare sectors to Lupin. Most recently, Alok was CEO of developed markets (US, Canada, Europe and Japan) at Dr Reddy's.

He joined Dr Reddy’s in 2012 and ran their India business till 2015 before moving back to the US to run their North America business. Prior to Dr Reddy’s, Alok spent nearly 15 years at Bristol-Myers Squibb, where he held several positions of increasing responsibilities.